Studies Currently Recruiting New Patients
The Department of Dermatology is currently conducting a 18-week multicenter, placebo-controlled research study to evaluate the safety and effectiveness of a topical (applied to the scalp) investigational medication in males with male pattern hair loss.
If you are 15-49 years of age with mild or moderate male pattern hair loss in the crown area, you may be eligible to participate. All study-related office visits, tests and study medication will be provided at no charge to you. For further information contact the Dermatology Clinical Research Office at 216.445.4649.
Other Recent Studies
APPLES: A Prospective Pediatric Longitudinal Evaluation To Assess The Long-term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
Protocol #: FHI 03-0-161/FG-506-06-37 IRB #:05-222.
Description: 10 year safety study to follow patients who have/had Atopic Dermatitis and applied tacrolimus (Protopic) ointment .03% or 0.1% for at least 6 weeks, continuously or intermittently. Pediatric subjects whose ages are/were <16 years at the time of first tacrolimus exposure.
Assessment & Tracking of Long-term Alefacept Safety Study (ATLAS).
Protocol #: C-736 IRB #:8392.
Description: 5 year safety study to follow patients who have/had moderate to severe plaque psoriasis and received at least 1 (one) dose of alefacept (Amevive).
A study on Calcipotriol, a Vitamin D Analogue, as an agent to induce the differentiation of basal cell carcinoma: A Randomized Placebo-controlled Trial.
Protocol #: IRB #: 470.
Description: 8 week study to evaluate a known differentiating agent, calcipotriol, as a possible agent that might eventually help in the treatment of basal cell carcinoma. Adult subjects with diagnosed basal cell carcinoma (between 0.8 and 2.0 square centimeters) which has not been previously treated.
For More Information, please contact:
Brian Moore, MD
Research Coordinator
216.445.8454
